FDA okays first therapy for group of progressive interstitial lung diseases

  • US Food and Drug Administration

  • Miriam Davis, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • Nintedanib oral capsules for treating chronic fibrosing (scarring) interstitial lung diseases (ILD) with progressive characteristics have gotten approval from the US Food and Drug Administration (FDA).
  • The drug lessens lung function decline.

Why this matters

  • The move represents the first approval for this group of fibrosing lung diseases that worsen over time.
  • The European Medicines Agency Committee for Medicinal Products for Human Use recommends approval.
  • FDA had previously approved nintedanib for ILD associated with systemic sclerosis or scleroderma.

Highlights

  • The approval was based on the Lancet-published INBUILD trial, a randomized, double-blind, placebo-controlled trial held over 52 weeks at 153 sites in 15 countries (n=663).
  • With 150 mg oral capsules twice daily, nintedanib was associated with a decreased annual rate of decline in FVC vs placebo of 107 (95% CI, 65.4-148.5) mL/year (P<.001>
  • The most common adverse events were diarrhea, nausea, stomach pain, vomiting, liver problems, decreased appetite, headache, and weight loss.
  • The FDA does not recommend the drug for patients with moderate or severe hepatic impairment.
  • Nintedanib may cause embryo-fetal toxicity in the form of arterial thromboembolic events, bleeding, and gastrointestinal perforation, among others.